Docon Sells 9.9% Thyrocare Stake for Rs 986 Crore

Docon Technologies, a key promoter of Thyrocare Technologies Ltd, has divested a 9.9% stake in the diagnostics company, garnering Rs 986 crore through a series of bulk and block deals conducted on Thursday. This transaction significantly reduces Docon's holding in Thyrocare from 60.92% to 51.02%.

Transaction Details and Share Price Impact

A total of 1,57,69,696 equity shares were sold in the transaction, with shares priced between Rs 624 and Rs 631.71 each. On the National Stock Exchange (NSE), more than 1.31 crore shares were moved through block deals, while 10 lakh shares were exchanged via bulk deals. Additionally, 16.01 lakh shares were transacted through a bulk deal on the Bombay Stock Exchange (BSE).

Following the announcement of this significant stake sale, Thyrocare's share price experienced a rise, with shares climbing nearly 3% to Rs 621.95 on the NSE and over 2% to Rs 622 on the BSE.

Institutional and Global Investor Participation

The stake sale attracted a diverse group of institutional investors, insurance companies, and global entities. Notable participants included HSBC Mutual Fund, DSP Mutual Fund, ICICI Prudential Mutual Fund, Aditya Birla Sun Life Mutual Fund, WhiteOak Capital Mutual Fund, and ITI Mutual Fund. Life insurance firms such as Kotak Mahindra Life Insurance Company and Tata AIA Life Insurance also took part. Global investors included Morgan Stanley, Citigroup Global Markets, HBM Healthcare Investments (Cayman), and the Kuwait Investment Authority, all participating through block deals on the NSE.

Details of other buyers involved in the bulk deals remain undisclosed on both the BSE and NSE at this time.

Context and Previous Transactions

This latest stake sale follows Docon's previous transaction in October of the previous year, where it sold a 10% stake in Thyrocare for Rs 667 crore. The continuous offloading of shares by Docon indicates a strategic shift in its investment approach concerning Thyrocare Technologies.

Thyrocare Technologies, a prominent player in the diagnostics sector, continues to draw significant interest from a wide array of investors, reflecting its strong market presence and growth potential in the healthcare industry.